In a groundbreaking development for the treatment of muscular dystrophies, IPS HEART received Orphan Drug Designation (ODD) from the U.S. FDA on January 13th, 2025, for its innovative stem cell therapy, GIVI-MPCs. GIVI-MPCs are mesenchymal progenitor cells derived from induced pluripotent stem cells (iPSCs) that have the potential to treat Becker Muscular Dystrophy (BMD). This milestone recognizes the therapy’s unprecedented ability to generate new skeletal muscle containing full-length dystrophin—a crucial protein missing or defective in individuals with BMD. [Read more…]
I Peace manufactures 100 lines of GMP iPS Cells cumulatively
Proof of customer recognition of its quality and mass manufacturing capability
Palo Alto, CA, January 7, 2025 — Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the number of GMP-grade iPS cells manufactured has reached 100 lines. This achievement solidifies I Peace as a true leader in the realm of iPS cell manufacturers, equipped with abundant experience in manufacturing GMP-grade iPS cells in compliance with global regulations. [Read more…]
Tolerance Bio Announces Scientific Advisory Board and $20.2M Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases
World-class leaders in the thymus, immunology, oncology, cell therapy, and drug development will inform and support the Company’s efforts to preserve, restore, and manipulate the thymus to address immune diseases
Pacific 8 Ventures joined the seed round syndicate led by Columbus Venture Partners, with participation by Criteria Bio Ventures, Sessa Capital, BioAdvance, and Ben Franklin Technology Partners
PHILADELPHIA, December 19, 2024 –Tolerance Bio, Inc., a biopharma company pioneering innovative approaches to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the formation of its Scientific Advisory Board (SAB) and the completion of its oversubscribed $20.2M seed financing round. [Read more…]
Axol Bioscience Secures SMART Grant to Accelerate the Development of a Commercial iPSC-Powered ALS Models
Axol Bioscience has been awarded a SMART Grant by Scottish Enterprise to Accelerate ALS Research through the development of ALS-related phenotypes using human iPSCs. This represents another significant step towards better disease modelling and ALS drug discovery.
The key objectives of this project are to:
- Develop a quality manufacturing system for iPSC-derived ALS relevant cell types
- Characterise and validate the cells using ALS relevant end points; TDP43 aggregation, Neurofilament Light elevation and Cryptic Exon Sequencing
- Develop and characterise an ALS co-culture model which includes motor neurons, microglia and astrocytes
- Commercialise an easy-to-use model system to drive forward ALS drug discovery
Answer ALS Releases World’s Largest ALS Patient-Based iPSC and Bio Data Repository
Unprecedented resource, created with Cedars-Sinai, to accelerate ALS research and drive development of targeted therapies globally
NEW ORLEANS –In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem cell (iPSC) and bio data repository. The repository encompasses biological and clinical data from nearly 1,000 ALS patients, offering an unprecedented resource for global researchers studying ALS, commonly known as Lou Gehrig’s disease. [Read more…]
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 78
- Next Page »